Abstract

NOVEL TREATMENT STRATEGIES FOR TUBERCULOSIS: A PARADIGM EMERGED FOR IMPROVED THERAPEUTIC INTERVENTION

Lekshmy Satheesh*, Arya Chandran, Angela A. Thomas and Dr. Sini S. G.

ABSTRACT

An infectious, fatal disease that primarily affects the lungs is tuberculosis. The bacterium Mycobacterium tuberculosis is to blame. Extrapulmonary tuberculosis, as the disease is commonly known, affects other bodily parts. They are typically asymptomatic and are referred to as latent infections. If the latent disease is not treated, it may become active. TB is an airborne illness that spreads when an infected person coughs or sneezes. This review article will concentrate on the most recent epidemiology, pathogenesis, innovative medications used to treat MDR-TB, and the management of TB in unusual situations. With the introduction of three novel substances—bedaquiline, delamanid, and pretomanid—the outlook for TB treatment has undergone a significant shift over the past ten years. Pretomanid and Delamanid are two of these medications that fall under the same pharmacological class, the nitroimidazoles. To combat this deadly condition that knows no bounds, it is imperative to clearly perceive and
provide better information on its treatment.

Keywords: Mycobacterium Tuberculosis, MDR TB, Bedaquiline, Delamanid, Pretomanid. Directly Observed Therapy Short Course (DOTS).